-
公开(公告)号:US20210023001A1
公开(公告)日:2021-01-28
申请号:US16934807
申请日:2020-07-21
发明人: Jean-Michel BUKOWSKI , Akshay NADKARNI , José L. BOYER , Brigitte DUQUESROIX-CHAKROUN , Tomas NAVRATIL
IPC分类号: A61K9/08 , A61K31/567 , A61K47/38 , A61K47/02 , A61K47/18 , A61K47/26 , A61K47/10 , A61P27/02 , A61K9/00
摘要: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
公开(公告)号:US20220323352A1
公开(公告)日:2022-10-13
申请号:US17850515
申请日:2022-06-27
发明人: Jean-Michel BUKOWSKI , Akshay NADKARNI , José L. BOYER , Brigitte DUQUESROIX-CHAKROUN , Tomas NAVRATIL
IPC分类号: A61K9/08 , A61P27/02 , A61K9/00 , A61K31/567 , A61K47/02 , A61K47/10 , A61K47/18 , A61K47/26 , A61K47/38
摘要: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
公开(公告)号:US20220241296A1
公开(公告)日:2022-08-04
申请号:US17629267
申请日:2020-07-21
发明人: Jean-Michel BUKOWSKI , Akshay NADKARNI , José L. BOYER , Brigitte DUQUESROIX-CHAKROUN , Tomas NAVRATIL
IPC分类号: A61K31/569 , A61K9/10 , A61K9/00 , A61K47/38 , A61K47/26 , A61K47/18 , A61K47/02 , A61K47/10 , A61P27/04
摘要: The present invention relates to an improved process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions are useful in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.
-
-